Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Acasti Pharma Inc. (ACST) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Quarterly results
11/14/2022 8-K Quarterly results
Docs: "Acasti Pharma Reports Second Quarter 2023 Operational Results Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, November 14, 2022 -- Acasti Pharma Inc. , a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced financial and operational results for the second quarter ended September 30, 2022. Recent Highlights • The Company expects to receive guidance from the Food and Drug Administration on its proposed phase 3 study design for GTX-104 in the form of a Type C meeting by the end of 2022 or early in the first calendar quarter of 2023. This FDA guidance should allow the Company to initiate the Phase 3 safety study and begin enrolling the first patients as planned in the first half ..."
08/11/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
02/14/2022 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "Press Release issued by Acasti Pharma Inc. on November 10, 2021"
08/12/2021 8-K Quarterly results
06/22/2021 8-K Quarterly results
02/09/2021 8-K Quarterly results
11/16/2020 8-K Quarterly results
Docs: "Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021 LAVAL, Quebec, Nov. 16, 2020 -- Acasti Pharma Inc. today provided a business update and announced its operating and financial results for the second quarter of fiscal 2021 ended September 30, 2020. Recent Events: TRILOGY 1 & 2 Topline Results. The Company’s two Phase 3 clinical trials, designated as TRILOGY 1 & 2, were designed to evaluate the efficacy, safety and tolerability of CaPre in patients with severe hypertriglyceridemia. The top-line results were announced on January 13, 2020 and August 31, 2020 respectively, and neither TRILOGY 1 nor TRILOGY 2 independently reached statistical significance, and therefore they did not meet their primary endpoint for lowering triglycerides. Although the triglyceride redu..."
08/13/2020 8-K Quarterly results
06/29/2020 8-K Quarterly results
Docs: "Acasti Pharma Provides Fiscal 2020 Year-End Business Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy